Successful, Cost-Saving Outpatient Parenteral Antimicrobial Therapy Following Hospital Discharge

SAN DIEGO, CA (October 19, 2012) – A retrospective pilot study was conducted of all patients, from January 2011 through April 2012, receiving OPAT under an indigent healthcare program (a hospital-funded program providing IV antibiotics through the POIC to qualified patients) to determine the outcomes of treatment of serious infections through a POIC and establish what costs were saved. Overall, nine patients showed a clinical success rate of 90% (cured 7, improved 2) with one patient (10%) lost to follow-up. The cost of treatment for all ten POIC patients was $75,800 whereby estimated hospital costs would have been $442,000 had patients been required to remain hospitalized. Under this program, total healthcare savings realized were $366,200, emphasizing that an appropriate level of care can be safely and effectively provided in a POIC versus extended hospitalization for this indigent population.

This study was presented at the 1st annual IDWeek™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2012
IDWeek 2012 is the first joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). With the theme—Advancing Science, Improving Care—IDWeek will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2012 takes place October 17-21 at the San Diego Convention Center in San Diego, California.

For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.